GlobeNewswire·Feb 25, 2026, 7:30 AM ET

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

AVXL

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced that CEO Christopher U. Missling, PhD, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:50 AM ET.
A live audio webcast of the presentation will be available on the Investors section of www.anavex.com, with an archived version released later that day.
The company focuses on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's, Parkinson's, schizophrenia, Rett syndrome, pain, and various cancers.
Lead candidate ANAVEX 2-73 (blarcamesine) completed Phase 2a, Phase 2b/3 trials for Alzheimer's disease, a Phase 2 study for Parkinson's disease dementia, Phase 2/3 studies for adult Rett syndrome patients, and a Phase 2/3 study for pediatric Rett syndrome patients.
ANAVEX 2-73 targets SIGMAR1 and muscarinic receptors to restore cellular homeostasis, showing potential in preclinical studies to halt or reverse Alzheimer's disease and exhibiting properties for treating epilepsy.
Candidate ANAVEX 3-71 targets SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against cognitive deficits, amyloid, and tau pathologies in transgenic mice.
The Michael J. Fox Foundation previously awarded Anavex a grant to fully fund a preclinical study for ANAVEX 2-73 targeting Parkinson's disease.
Forward-looking statements in the release are subject to risks and uncertainties detailed in the company's Form 10-K, with no obligation to update information after the release date.